AGU
ADPT icon

Alpine Group USVI’s Adaptive Biotechnologies ADPT Stock Holding History

Alpine Group USVI’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-20,000
Closed -$966K – 12
2019
Q2 		$966K Buy
+20,000
New +$886K 3.04% 9

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
SIG
Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Alpine Group USVI's ADPT Position: Q3 2019 in Review

Alpine Group USVI sold out of Adaptive Biotechnologies (ADPT) in Q3 2019, closing a stake of 20,000 shares — an estimated $966K sold.

Alpine Group USVI first reported a position in ADPT in Q2 2019 and held it in 1 quarter. The position peaked at $966K in Q2 2019. 117 funds tracked by Wall St. Rank hold ADPT as of Q3 2019.

  • Alpine Group USVI reported no remaining Adaptive Biotechnologies position as of Q3 2019 after selling out during the quarter.
  • Alpine Group USVI sold 20,000 Adaptive Biotechnologies shares in Q3 2019, an estimated $966K.
  • Alpine Group USVI first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 1 quarter.
  • Alpine Group USVI's Adaptive Biotechnologies position peaked at $966K in Q2 2019.
  • 117 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2019.

Based on Alpine Group USVI's 13F filing for Q3 2019, filed 11 Oct 2019.